ArticleBMJ open ophthalmology2022

Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy.

Thomas Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.